Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine

Clinical Neuropharmacology

Volumn 29, Issue 5, 2006, Pages 269-275

  Mei, Daniele ^a,b,c   Ferraro, Diana ^a   Zelano, Giovanni ^a,b   Capuano, Alessandro ^a   Vollono, Catello ^a   Gabriele, Carbone ^b   Di Trapani, Girolamo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Italian Hospital Group   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Chronic migraine; Cortical hyperexcitability; Medication overuse; Topiramate

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TOPIRAMATE; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ADULT; ANALGESIC ACTIVITY; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EPISODIC MIGRAINE; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; ITALY; MAINTENANCE THERAPY; MALE; MEMORY DISORDER; MENTAL CONCENTRATION; MIGRAINE; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; TASTE DISORDER; TRANSFORMED MIGRAINE; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRYPTAMINES;

EID: 33748968518     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.000022888.49044.99     Document Type: Article

References (14)

1. White HS. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 2005;45(suppl 1):S48-S56.
2. Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuroreport 2005;16(12):1383-1387.
3. Akerman S, Goadsby PJ. Topiramate inhibits trigeminovascular activation: an intravital microscopy study. Br J Pharmacol 2005;146(1):7-14.
4. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 2004;24(12):1049-1056.
5. Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: a randomized double blind versus placebo study. Neurol Sci 2004;25(5):245-250.
6. Silberstein SD, Neto W, Schmitt J, et al, (for the MIGR-001 Study Group). Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-495.
7. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention-A randomized controlled trial. JAMA 2004;291:965-973.
8. Diener HC, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-950.
9. Silvestrini M, Bartolini M, Coccia M, et al. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23(8):820-824.
10. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. 2nd ed. Cephalalgia 2003;suppl 1:1-160.
11. 1B/1D agonist) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-658.
12. Aurora SK, Barrodale P, Chronicle EP, et al. Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache. 2005;45:546-552.
13. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 2004;24:1049-1056.
14. Levy D, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT1B_1D receptor agonists. Proc Natl Acad Sci U S A 2004;101:4274-4279.